Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021

1
Anti-Hypertensive Therapeutics in Asia-Pacific
Markets to 2021
No. Pages 82
Published on July - 2015
2
.
Report Overview
About Anti-Hypertensive Therapeutics in
Asia-Pacific Markets to 2021 Research Beam added
a report Anti-Hypertensive Therapeutics in
Asia-Pacific Markets to 2021 . Hypertension is a
chronic medical condition characterized by
elevated blood pressure in the arteries. It
affected an estimated 517 million people in 2014,
a figure that will grow at a Compound Annual
Growth Rate (CAGR) of 1.2 to 561 million in 2021
in the four Asia-Pacific (APAC) regions of China,
India, Australia, and Japan. This high prevalence
is a substantial contributor to healthcare costs
and a major cause of morbidity. Despite this,
awareness of hypertension is low among
physicians, patients, and the public alike,
leading to poor blood pressure control. The
classes of drugs prescribed to treat hypertension
are Angiotensin Converting Enzyme Inhibitors
(ACEI), Angiotensin Receptor Blockers (ARB),
Calcium Channel Blockers (CCB), beta-blockers,
renin inhibitors, and diuretics. Get Full
Details On http//www.researchbeam.com/anti-hype
rtensive-therapeutics-in-asia-pacific-to-2021-incr
easing-prevalence-of-hypertension-drives-growth-de
spite-weak-pipeline-market
3
.
Report Overview

• The percentage of patients treated using
  monotherapy and combination therapy (including
  fixed-dose combinations) varies from country to
  country. The most commonly prescribed drugs in
  the CCB class are amlodipine and lercanidipine,
  while the leading ARBs are telmisartan,
  candesartan, olmesartan, irbesartan, losartan,
  valsartan, azilsartan medoxomil, and eprosartan.
  Ramipril, imidapril, perindopril, enalapril,
  lisinopril, benazepril, fosinopril, trandolapril,
  and quinapril dominate the ACEIs.
• Scope
• Hypertension prevalence is a prominent
  contributor to market size in the assessed
  countries. The market is mostly dominated by
  generics, and there are only a few patented
  products.
• Will generics continue to dominate treatment?-
  How do the elderly populations and their
  associated risk factors affect prevalence?
• The current anti-hypertensive therapeutics
  pipeline is weak, comprising 124 molecules in
  various stages of development, dominated by small
  molecules.
• Will the upcoming molecules change the treatment
  paradigm in the near future?
• How will the weak pipeline affect the market?

4
.
Report Overview

• Analysis of clinical trials since 2006 identified
  that anti-hypertensive products have a high rate
  of attrition.
• How do failure rates vary by product stage of
  development, molecule type, and mechanism of
  action?- How do other factors such as average
  trial duration and trial size influence the costs
  and risks associated with product development?
• Over the 20142021 forecast period, the APAC
  anti-hypertensive therapeutics market is expected
  to increase in value at a CAGR of 3.4 from 15.7
  billion to just over 19.9 billion. Growth is
  projected to vary considerably across the four
  assessed markets.
• Which markets make the most significant
  contribution to the current market size?
• What are the epidemiology trends in these
  markets?- Will branded products patent
  expirations pose a significant threat?- Will new
  market entrants over the forecast period lead to
  substantial changes in annual therapy costs?

5
Report Overview

• Reasons to buy This report will enable you to
• Understand the clinical context of hypertension
  by considering symptoms, etiology,
  pathophysiology, co-morbidities and
  complications, epidemiology, diagnosis, and
  treatment options.
• Identify the therapeutic strategies, products,
  and companies that dominate the current marketed
  products landscape, and recognize gaps.-
  Appreciate key anti-hypertensive pipeline trends
  in molecule type, administration route, mechanism
  of action, and novelty.
• - Consider market opportunities and potential
  risks by examining trends in anti-hypertensive
  clinical trial size, duration, and failure rate
  by stage of development, molecule type, and
  mechanism of action.- Compare treatment usage
  patterns, annual therapy costs, and market growth
  projections for the China, India, Australia, and
  Japan.- Discover trends in licensing and
  co-development deals concerning anti-hypertensive
  products and identify the major strategic
  consolidations that have shaped the commercial
  landscape.

6
Table Of Contents
1 Table of Contents1 Table of Contents 51.1
List of Tables 71.2 List of Figures 72
Introduction 92.1 Pathophysiology 92.2 Etiology
102.3 Signs and Symptoms 112.4 Co-morbidities
and Complications 112.5 Diagnosis 132.5.1
Office or Clinic Blood Pressure Monitoring
132.5.2 Ambulatory Blood Pressure Monitoring
142.5.3 Home Blood Pressure Monitoring 142.5.4
Miscellaneous Methods 14
7
Table Of Contents
2.5.5 Diagnosis of Target Organ Damage 142.5.6
Diagnosis of Hypertension in Pregnancy 152.6
Classification 152.7 Epidemiology 162.8
Prognosis 172.9 Treatment and Management
172.9.1 Treatment Strategy 193 Marketed
Products 263.1 Key Marketed Products 263.1.1
Prestalia (perindopril arginine amlodipine
besylate) 263.1.2 Azilva (azilsartan medoxomil)
263.1.3 Amlodipine besylate 263.1.4 Telmisartan
273.1.5 Aliskiren 28
8
Table Of Contents
3.1.6 Olmesartan medoxomil 293.1.7 Valsartan
303.1.8 Losartan 31 3.1.9 Exforge (amlodipine
valsartan) 323.2 Heat Map for Marketed Products
334 Anti-hypertensive Market to 2021 â
Pipeline Products 354.1 Overall Pipeline
354.1.1 Pipeline Analysis by Molecule Type
364.1.2 Pipeline Analysis by Mechanism of Action
374.2 Clinical Trial Analysis 394.2.1 Failure
Rate 39Enquiry about this report _at_
http//www.researchbeam.com/anti-hypertensive-ther
apeutics-in-asia-pacific-to-2021-increasing-preval
ence-of-hypertension-drives-growth-despite-weak-pi
peline-market/enquire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/anti-hypertensive-ther
apeutics-in-asia-pacific-to-2021-increasing-preval
ence-of-hypertension-drives-growth-despite-weak-pi
peline-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com